NCT00006154View on ClinicalTrials.gov

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Indinavir sulfate

400 mg tablets equaling 1600 mg daily

DRUG

Ritonavir

100 mg liquid capsules equaling 400 mg daily

DRUG

Abacavir sulfate

300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.

DRUG

Efavirenz

200 mg capsules equaling 600 mg daily

DRUG

Stavudine

30-40 mg capsules equaling 60 or 80 mg daily

DRUG

Didanosine

250-400 mg E.coated tablets equaling 250 or 400 mg daily

DRUG

Aldesleukin

Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.

Trial Locations (4)

Unknown

Viridae Clinical Sciences / University of British Columbia, Vancouver

Centre de traitment d'immunodeficience, Montreal

Centre Hospitalier de la Universite de Montreal (CHUM), Montreal

Institut Thoracique de Montreal, Montreal

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH